SCHEMBL29797033

SCHEMBL29797033

COC(=O)c1ccc2c(c1)N(Cc1ccc(OC3CCCC3)cc1)C(=O)[C@@H](NC(=O)OC(C)(C)C)CS2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 3/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ TP53 P04637 2/20 0.39
▸ XIAP P98170 1/20 0.38
▸ NPY1R P25929 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ USP2 O75604 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NAAA Q02083 1/20 0.36
▸ P2RX3 P56373 2/20 0.36
▸ PDE4A P27815 1/20 0.36
▸ PDE4B Q07343 1/20 0.36
▸ PDE4C Q08493 1/20 0.36
▸ PDE4D Q08499 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ CASP1 P29466 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26961610 0.93 NPC1 (0.43) SRCNPC1TP53XIAPNPY1R
SCHEMBL20279843 0.90 TP53 (0.42) SRCNPC1TP53XIAPNPY1R
SCHEMBL31375529 0.88 XIAP (0.42) SRCNPC1TP53XIAPNPY1R
SCHEMBL20280050 0.88 KCNN4 (0.41) SRCNPC1TP53XIAPNPY1R
SCHEMBL31628063 0.88 XIAP (0.42) SRCNPC1TP53XIAPNPY1R
SCHEMBL29796876 0.88 KCNN4 (0.41) SRCNPC1TP53XIAPNPY1R
SCHEMBL20279969 0.88 NPC1 (0.43) SRCNPC1TP53XIAPNPY1R
SCHEMBL20280006 0.88 TP53 (0.51) NPC1TP53XIAPNPY1RALDH1A1
SCHEMBL29796849 0.88 TP53 (0.51) NPC1TP53XIAPNPY1RALDH1A1
SCHEMBL31374890 0.88 TP53 (0.44) SRCNPC1TP53XIAPNPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368150-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2024-11-07 — — US disclosed
EP-4291558-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2023-12-20 — — EP disclosed
WO-2022171745-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2022-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368150-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER BICRA, BRD4, CNR1 SRC 2202/4885NPC1 1363/4885TP53 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback